Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Kashdog, not pure gambling (unless the trader were reckless enough to commit their entire holding to trading).
I agree with you (and have said as much on this forum) that Buy and Hold is a difficult way forward to argue with, but the commitment of a block of shares to "trading the range" over the last six months or so has been a worthwhile process with which I am sure that anyone who subscribes to the "every little helps" approach will concur.
One day there will be a breakout and that trade won't work and that is to be expected, but if kept within sensible proportions no damage done.
I guess my overriding point was that the stability (but clearly defined ranges) that SCLP has shown over the last six or seven months has been not only a bit of a gift but also a very unusual opportunity for any LTH (who like me might not have been clever enough to sell at the 27.5p level) should they have chosen to follow that path.
I'm very much hoping for that illusive breakout on the upside..... I will welcome its arrival at any time, but until it does the continuance of the range will I'm sure be enjoyed by some; particulaly those who know where the top and the base levels are (of which I do not claim ti be one.
Anyway, while we wait IMO I'm sure some (to varying degrees) will have benefitted from SCLP's new found status and hence relaive stability.
AB, not sure I agree with your first statement, following the rise in Feb it has fluctuated in a tight range, such that trading within the spread would be pure gambling without much room for profit.
I guess some may have made a little but looking at the size of the majority of trades from feb to date, I doubt many would have collected a retirement fund.
Buy and hold is the right strategy in my opinion ( for what it’s worth) but even that view is based on what I feel is generally held optimistic view that one or more of the platforms will come through.
I see little or no negative comment on this board but there are a couple of reasons why an “insurance” strategy should be considered e.g. failure of one or more trials, for whatever reason and failure of the company to effectively monetise.
Let me state that I am optimistic but have been burned in the past when I thought “this cannot fail”.
Surely the range we are in since Feb this year suggests that no slow drip drip, but equally no spurred rise forward.
As we are range bound why is this?
In fact it has not been difficult to predict the next SP move many times over that period which has been highly profitable for some I am sure. That assumes that as each extreme is reached it is not taken as a signal for a further fall or an about to dramatically rise Share Price, because if it has then that will demonstrate who is facilitating the profit for the range traders.
I just wish I knew how long Scancell can continue to provide such easy short term profits for those who are patient and observe and trade accordingly.
I've generally been wrong on share price predictions over the last 10 years but going by history I suspect we will spike to 40p and settle at 35p for a while. I think it will happen almost instantly with no warning. Only insiders will be aware of what is going on.
Take this with a huge pinch of salt as I had hoped we would be sitting around 90p some two years ago.
One nice thing about the share price now is that we don't seem to suffer the slow drip drip on the price after a rise.
Good weekend and continued good health to all.
Random auto correct*
Burble Indonesia think that is the case here.. registration and allocation of the DHO number is not "provisional". From everything I have read, the allocation of the DHO number is the final green light needed to start treating patients, and we know that we have that number allocated.
Thanks for responses.
HAGW all.
Something also to bear in mind is that
submissions don’t mean a binary approval. Ethics/Regulatory committees may provide provisional approval subject to changes - these can be as minor as a change to wording to patient information leaflets, or additional data required. So whilst we have an idea of where in the process we are by the mile stones reported in RNSs, we’re not privy to any of this background movement. Hence first patient recruited may come anytime soon, or alternatively there may be a longer period of quiet before we get that news. Difficult to really gauge.
Well, we can hopefully track the recruitment of patients in the SA trial. Just a matter of how much preparation was set in place PRIOR to getting the go ahead. Hopefully everything was "good to go" in anticipation of the trial being granted. If not... guess it depends on how long it will take to set up. Binary really, but the RNS will come . Deserves at least afew pence on the share price on the day off the RNS .
Hi C11. I think Scancell as an investment (and therefore the SP) is hampered by the absence of any active trials for all these years. Doubly so with the enormous potential of the science. For my money, a trial is only up and running when it has actual patients, i.e when they are being dosed - see SCIB1/Keytruda which is running in theory but (as far as we know) is not progressing.
As you say FPI will be a milestone, especially with the SCIB1 combo trial in mind, so I do hope (and believe) it will be RNS'd.
Lindy's driving force is to cure people and I am certain she is even more keen to see FPI in all 3 trials than we are - it must be incredibly frustrating to have her life's work sitting on the shelf.
Likely to be relatively quiet on here today (unless Crumbs revs his engine up ;-)) and so anyone have any thought on the impact on the SP, with the arrival of 1st Patient Dosed news?
Obviously a milestone but are we really expecting that to move the SP up modestly, or not at all on its own?
This of course is based on an assumption that that news, will be made public. Maybe it won’t.